Emerging perspectives in the diagnosis and management of hypertrophic cardiomyopathy
Perry Elliott, MD
Aleš Linhart, MD, PhD
Iacopo Olivotto, MD
Novel approaches in managing patients with HCM
Integrating icosapent ethyl in cardiovascular risk reduction strategies: Practical guidance
Pam R. Taub, MD, FACC, FASPC
Improving the management of patients with atherosclerotic cardiovascular disease - The evolving role of icosapent ethyl
Erik Stroes
P. Gabriel Steg, MD
Challenges in ASCVD reduction and TG-related risk
Perspectives on the results of recent clinical outcomes trials with EPA prevention
Oral cholesterol-lowering therapies: The basis of prevention
Lale Tokgözoğlu, MD
PCSK9i: Benefits across the spectrum of cardiovascular disease
Prof. dr. Fabrice Martens
The evolving need and challenges to reach LDL-c targets in high-risk patients
Kausik Ray, MBChB, MD, MPhil
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
Erin Michos
The LDL-c challenge in high cardiovascular risk - Integrating innovative therapies in clinical management
Role of CETP inhibitors in cardiovascular risk reduction - Will lessons from the past lead to future success?
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
Roxana Mehran, MD
Exploring the role of a novel CETP inhibitor in lipid management
New insights on CETP inhibition from genetic research and clinical trials
Unmet needs in lowering LDL-c
Improving quality of life in patients with HCM
Carolyn Ho, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.